Hematotoxicity and Selectivity Assays
Hematotoxicy is a major toxicity concern of oncology drug candidates, for both hematological and solid tumors. Hematopoietic Stem Cells (HSCs) are the responsible to replenish mature blood cells after hematopoietic stresses. One of the most common dose limiting adverse effects in cancer treatment is myelosuppression.

We can measure whether your compounds kill selectively

We test the hypothesis your compounds are selective, but it does not imply toxicity

Tumor vs Progenitor Cells in AML BM Samples: Eliminate immature progenitors responsible for relapse

Ex vivo Therapeutics Index: Tumor vs Progenitor Cells

Extreme resistance myeloid progenitors
Suggest no hematotoxicity, very selective
plasma cells Ideal patient
More sensitive for myeloid progenitors
than for plasma cells High hematotoxicity
Unfit patient

Daratumumab is less active on Healthy CD34+CD38- progenitor cells

Dose response curves of daratumumab in plasmatic and progenitor cells

Daratumumab Specificity & Therapeutic Window Ex Vivo is Higher at High CD38 Expression

Correlation between CD38 expression on different cellular subsets and activity (AUC)
in MM patients. Daratumumab is Less Active on T, NK, or Progenitor Cells